1. Introduction {#sec1}
===============

*Angelica dahurica* (Fisch. ex Hoffm.) Benth. & Hook. f. ex Franch. & Sav. is a perennial herb belonging to the Umbelliferae family and contains various types of total coumarins \[[@bib1], [@bib2], [@bib3], [@bib4]\]. Thus, the dried roots have been used in Korean traditional medicine as a treatment for erythema, pains, sinusitis, and inflammation \[[@bib1], [@bib2]\].

The peroxisome proliferator-activated receptors γ (PPARγ) plays a role in lowering insulin resistance by modulating the metabolism of fatty acids \[[@bib3], [@bib4]\]. PPARγ regulates adipocyte differentiation and increases the number of small insulin-sensitive adipocytes, which are improtant in imparting insulin sensitivity [@bib4]. Thus, PPARγ is one of the targets of anti-diabetic agents [@bib5], and combining such agents with others that have different targets, can further improves insulin sensitivity [@bib6]. PPARγ agonist activity, determined indirectly by adipocyte differentiation and triglyceride accumulation, indicates potential antidiabetic property [@bib7]. Rosiglitazone, an agonist of PPARγ, has been widely used as an anti-diabetic drug for the treatment of the type II, but its adverse effects on the cardiovascular system, including increasing the risk of myocardial infarction, is a clinical concern \[[@bib8], [@bib9]\].

To search for a PPARγ mimetic with anti-diabetic activity from a natural source, we determined the adipocyte differentiation potential in 3T3-L1 cells treated with methanol extract from *A. dahurica* or with its subfractions. Three compounds, bergapten (**1**), imperatorin (**2**) and phellopterin (**3**), were obtained from the EtOAc fraction of *A. dahurica*. Phellopterin (**3**) is a naturally occurring furanocoumarin and its role as a partial benzodiazepine receptor has been described [@bib10]. However, the anti-diabetic activity of phellopterin (**3**) has not been clearly identified. In this study, not only the adipocyte differentiation rate and up-regulation of the PPARγ mRNA level by phellopterin (**3**) treatment were determined, also the improvement in the type Ⅱ diabetic status of streptozotocin (STZ)-induced diabetic mice treated with phellopterin (**3**) was assessed.

2. Results and discussion {#sec2}
=========================

Increase in adipocyte differentiation rate indicates that cells become more sensitive to insulin [@bib4]. To identify the effects of *Angelica dahurica* on adipocyte differentiation, 3T3-L1 cells were exposed to various concentrations of *Angelica dahurica* root extract (ADE) or its subsequent fractions. ADE was fractionated with *n*-hexane, dichloromethane, ethyl acetate, *n*-butanol, and distilled water ([Fig. 1](#fig1){ref-type="fig"}). The ADEs did not show any significant cell cytotoxicity up to 100 μg/mL (data not shown). Although both the ADE and its ethyl acetate (EtOAc) subfraction significantly promoted adipocyte differentiation in a dose-dependent manner, the EtOAc fraction was most efficient ([Table 1](#tbl1){ref-type="table"}).Fig. 1Isolation of bergapten, imperatorin, and phellopterin from *Angelica dahurica* root. CH~2~Cl~2~, dichloromethane; EtOAc, ethyl acetate; BuOH, *n*-butanol; DW, distilled water; MeOH, methanol.Fig. 1Table 1Changes in adipocyte differentiation with treatments of *Angelica dahurica* extract and its fractions in 3T3-L1 cells.[1](#tbl1fn1){ref-type="table-fn"}Table 1ExtractFractionSub-fractionated and purifiedAdipocyte differentiation (%)Treatment concentration12.5 μg/mL25 μg/mL50 μg/mL100 μg/mLADE[2](#tbl1fn2){ref-type="table-fn"}NE[3](#tbl1fn3){ref-type="table-fn"}115.8 ± 1.43^∗^120.4 ± 2.04\*130.5 ± 1.29\*ADEn-hexaneNE86.7 ± 5.64^∗^94.6 ± 3.78\*\*90.1 ± 2.68\*\*CH~2~Cl~2~NE84.5 ± 5.36^∗∗^90.4 ± 7.26\*\*92.3 ± 3.93\*\*EtOAcNE214.5 ± 4.03^∗^228.4 ± 3.15\*\*245.6 ± 3.67\*\*n-BuOHNE72.6 ± 3.68^∗^80.1 ± 4.97\*\*80.6 ± 4.64\*\*H~2~ONE68.3 ± 4.23^∗^70.3 ± 4.69\*77.6 ± 5.06\*EtOAcBergapten (1)123.76 ± 9.00127.92 ± 16.8691.70 ± 8.35NE[3](#tbl1fn3){ref-type="table-fn"}Imperatorin (2)150.89 ± 18.15^∗^169.73 ± 51.62^∗^189.60 ± 22.95\*NEPhellopterin (3)223.43 ± 23.10^∗^334.06 ± 64.28^∗∗^336.30 ± 15.16\*\*NERosiglitazone239.31 ± 26.95^∗^247.7 ± 4.65^∗∗^250.7 ± 6.34^∗∗^330.7 ± 5.64^∗∗^[^1][^2][^3][^4]

Since the EtOAc fraction effectively stimulated adipocyte differentiation compared to the other fractions, we further subfractionated the EtOAc fraction with 75% aq. MeOH and then separated the individual compounds using ODS Prep HPLC (5 nm ODS, 75% aq. MeOH, Waters Spherisorb, Ireland). The structures of the three compounds isolated were identified using ^1^H-NMR and ^13^C-NMR spectroscopy.

Bergapten (**1**): ^1^H-NMR (500 MHz, CD3OD) *δ*8.08 (1H, d, J = 9.8 Hz, H-4), 7.72 (1H, d, J = 2.5 Hz, H-2′), 7.14 (1H, d, J = 2.5 Hz, H-3′), 7.00 (1H, s, H-8), 6.20 (1H, d, J = 9.8, H-3); ^13^C-NMR (125 MHz, CD3OD) *δ*161.33 (C-2), 158.22 (C-7), 152.20 (C-8a), 149.13 (C-5), 144.45 (C-2′), 140.02 (C-4), 114.45 (C-6), 113.58 (C-3), 106.84 (C-4a), 106.60 (C-3′), 93.01 (C-8), 59.88 (5-OCH3).

Imperatorin (**2**): ^1^H-NMR (500 MHz, CD3OD) *δ*7.95 (1H, d, *J* = 9.6 Hz, H-4), 7.85 (1H, d, *J* = 2.1 Hz, H-2′), 7.47 (1H, s, H-5), 6.90 (1H, d, *J* = 2.1 Hz, H-3′), 6.34 (1H, d, *J* = 9.6 Hz, H-3), 5.52 (1H, t, *J* = 7.0 Hz, H-2″), 4.92 (2H, d, *J* = 7.0Hz, H-1″), 1.69 (3H, s, H-5″), 1.65 (3H, s, H-4″); ^13^C-NMR (125 MHz, CD3OD) *δ*161.42 (C-2), 148.44 (C-7), 147.02 (C-2′), 145.34 (C-8), 143.45 (C-4), 139.53 (C-8a), 130.92 (C-3″), 126.30 (C-6), 119.49 (C-2″), 116.44 (C-4a), 113.65 (C-5), 113.42 (C-3), 106.54 (C-3′), 69.47 (C-1″), 24.52 (C-5″), 16.70 (C-4″).

Phellopterin (**3**): ^1^H-NMR (500 MHz, CD3OD) *δ*8.11 (1H, d, J = 9.6 Hz, H-4), 7.80 (1H, d, J = 2.3 Hz, H-2′), 7.19 (1H, d, J = 2.3 Hz, H-3′), 6.24 (1H, d, J = 9.6 Hz, H-3), 5.53 (1H, t, J = 7.0 Hz, H-2″), 4.89 (1H, d, J = 7.0 Hz, H-1″), 4.20 (3H, s, 5-OCH3), 1.70 (3H, s, H-4″), 1.64 (3H, s, H-5″); ^13^C-NMR (125 MHz, CD3OD) *δ*161.33 (C-2), 150.90 (C-7), 145.45 (C-2′), 145.45 (C-3″), 144.69 (C-8a), 144.00 (C-5), 140.05 (C-4), 139.46 (C-8), 119.55 (C-2″), 114.46 (C-6), 111.48 (C-3), 106.95 (C-4a), 105.01 (C-3′), 69.64 (C-1″), 59.91 (5-OCH3), 24.50 (C-4″), 16.61 (C-5″).

We also evaluated the differences in adipocyte differentiation when cells were treated with 12.5, 25 and 50 μg/mL concentrations of the identified compounds ([Table 1](#tbl1){ref-type="table"}). In the case of Bergapten (1), cytotoxicity was observed at a concentration of 50 μg/mL or later. And Imperatorin (2) and Phellopterin (3) were cytotoxic at a concentration of 100 μg/mL (Not showing data). For this reason, we conducted experiments at concentrations of 12.5, 25 and 50 μg/mL. Rosiglitazone strongly promoted adipocyte differentiation at a relatively low dose (12.5 μg/mL). Bergapten (**1**) did not induce adipocyte differentiation compared to the control. Both imperatorin (**2**) and phellopterin (**3**) significantly increased the rate of adipocyte differentiation compared to the control at 12.5, 25 and 50 μg/mL. Interestingly, treatment of phellopterin (**3**) increased adipocyte differentiation to higher levels than that seen in rosiglitazone-treated cells. This result suggests that phellopterin (**3**) has an adipocyte differentiation potential similar to rosiglitazone.

Adipocyte differentiation can be prompted by the action of PPARγ [@bib4]. PPARγ isoforms have been identified as key regulators of glucose absorption, lipid metabolism, proliferation, and cellular differentiation [@bib11]. PPARγ agonist thiazolidinedione have been widely used as insulin sensitizers for treatment of type II diabetes mellitus for more than 20 years \[[@bib12], [@bib13]\]. It shown a significant improvement of tissue (muscle and adipocytes) sensitivity to the effects of insulin, which is used in the treatment of type II diabetes mellitus [@bib11]. Thus, we tested the effect of phellopterin (**3**) on changes in the PPARγ mRNA level using quantitative RT-PCR. Treatment with phellopterin ((**3**), 50 μg/mL) significantly augmented the mRNA expression level of PPARγ compared to control (4.30 ± 0.67 *vs.* 1.00 ± 0.35), whereas treatment with imperatorin (**2**) did not (1.40 ± 0.59). Based on these results, it is speculated that the adipocyte differentiating potential of phellopterin (**3**) may be, at least in part, induced by its augmentation of the mRNA expression of PPARγ in preadipocytes ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2Changes in mRNA expression level of PPARγ by phellopterin and imperatorin. The mRNA expression level of PPARγ on 3T3-L1 cells were determined by qRT-PCR method. ^∗∗^*P* \< 0.01 *vs.* control.Fig. 2

Next, we tested whether these actions of phellopterin (**3**) could improve insulin resistance and attenuate blood glucose levels, in the diabetic status of HFD/STZ-induced type Ⅱ diabetic mice. Because, the animal model by feeding with high-fat diet following STZ that would closely mimic the metabolism characteristics of human type II diabetes mellitus [@bib14]. As shown in [Table 2](#tbl2){ref-type="table"} and [Fig. 3](#fig3){ref-type="fig"}, HFD/STZ mice showed impairments in the regulation of their blood glucose and in their lipid metabolisms, which resulted in highly increased glucose, triglyceride, and total-cholesterol levels. However, through the administration of phellopterin ((**3**), 1 and 2 mg/kg) improved the levels of blood glucose, triglyceride and total-cholesterol in HFD/STZ mice, and this role of phellopterin appears to be concentration-dependent. This result indicates that administration of phellopterin (**3**) could be helpful in reducing blood glucose levels and improving lipid profiles, which are beneficial in the treatment and prevention of diabetes.Fig. 3Effect of phellopterin treatment on the changes of blood glucose level in high-fat diet/streptozotocin (HFD/STZ)-induced diabetic mice (n = 6). ^∗^*P* \< 0.05 *vs.* normal diet group and ^\#^*P* \< 0.05 *vs.* HFD with STZ injected group.Fig. 3Table 2Effect of phellopterin treatment on the changes of triglyceride and total-cholesterol level in high-fat diet/streptozotocin (HFD/STZ)-induced diabetic mice (n = 6).Table 2Normal diet groupHFD with STZ injected groupTreatment concentration of phellopterin (mg/kg)00.512Body weight (g)32.7 ± 1.1337.9 ± 1.63^∗^37.3 ± 2.1333.1 ± 1.67^\#^31.1 ± 2.27^\#^Food intake (g/day)4.11 ± 0.615.34 ± 0.56^∗^5.24 ± 0.645.15 ± 0.815.05 ± 0.81Total-cholesterol (mg/dL)520.4 ± 6.211154.8 ± 97.64^∗^997.5 ± 70.68864.4 ± 53.14^\#^630.4 ± 46.78^\#^Triglyceride (mg/dL)170.6 ± 25.64541.6 ± 26.87^∗^481.6 ± 17.45^\#^446.7 ± 18.65\#346.7 ± 20.17^\#^[^5][^6]

3. Conclusion {#sec3}
=============

Phellopterin (**3**), a naturally occurring furanocoumarin isolated from *A. dahurica* promoted adipocyte differentiation and augmented the mRNA expression level of PPARγ. PPARγ has been identified as a therapeutic target for the prevention and treatment of both insulin resistance and metabolic syndrome. The results of present study revealed that *A. dahurica* and its major component, phellopterin, efficiently induced adipocyte differentiation, suggesting that it functions as a PPARγ agonist. These anti-diabetic actions resulted in the improvement of blood glucose and lipid levels in HFD/STZ mice. Therefore, the insulin-like differentiation-inducing activity of phellopterin (**3**) may be valuable as an interventional strategy for diabetic patients, and should be investigated further as a starting compound for the development of anti-diabetic drugs and PPARγ mimetics (see [Fig. 4](#fig4){ref-type="fig"}).Fig. 4Summary of the present study. Phellopterin, isolated from *Angelica dahurica* root, promotes adipocyte differentiation and mRNA expression level of PPARγ. Also improvement of blood glucose and lipid levels in HFD/STZ mice. Thus, phellopterin has the potential to be developed as PPARγ mimetics in the future.Fig. 4

4. Materials and methods {#sec4}
========================

4.1. Materials {#sec4.1}
--------------

3-Isobutyl-1-methylxanthine, insulin, and dexamethasone were purchased from Sigma (St. Louis, MO, USA). Unless indicated otherwise, chemicals were obtained from Sigma. Dulbecco\'s modified Eagle\'s medium (DMEM) along with bovine calf serum (BCS), fetal bovine serum (FBS) and antibiotics were obtained from GIBCO/BRL Life Technologies, Inc. (NY, USA). AdipoRed Assay Reagent, a product of Lonza Walkersville Inc. (Walkersville, MD, USA), was used to measure adipocyte differentiation.

4.2. Preparation of *Angelica dahurica* extracts {#sec4.2}
------------------------------------------------

*Angelica dahurica* plants were collected from a farm located at Bongwha, Gyeongsangbuk-do, and proliferated at the experiment farm of the Agricultural Research Station, Dongguk University, located at Goyang, Gyeonggi-do. Samples were collected in August 2014. Dr. Se Chan Kang identified the specimens and the voucher specimen of *Angelica dahurica* (NMR-KR-14-00159) was deposited at the herbarium of Department of Oriental Medicine Biotechnology, Kyung Hee University. The crude extract was obtained by extracting 1 kg of dried plant twice with methanol for 4 hours at 60 °C. The extracts were concentrated for 16 hours at reduced pressure and 40 °C using a rotary evaporator, and then stored at −20 °C until use. The yield of the extracts was about 19%.

4.3. Animals and treatment with the isolated compounds {#sec4.3}
------------------------------------------------------

Male ICR strain mice were purchased from Korea Laboratory Animal Co. (Daejeon, Korea) and were allowed to acclimatize for 2 weeks prior to the experiments. The animals were maintained under standard laboratory conditions: temperature of 21 ± 2 °C, relative humidity of 50 ± 5% and a normal photoperiod (12 h dark/light). The experimental procedures and animal care protocols were approved by the Animal Care and Use Committee of Kyung Hee University, and conformed to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH Publication No. 85-23). After having been fed a high-fat diet (HFD; rodent diet in which 60% of the energy comes from fat, Research Diet, USA) for 4 weeks, the mice were administered streptozotocin (STZ, Sigma, 100 mg/kg) dissolved in 0.1 M citrate buffer (pH 4.5) by peritoneal injection to induce type Ⅱ diabetes.

Diabetic status was determined two weeks after receiving STZ using a glucometer (Glucotrend, Roche, Germany). Mice with blood glucose concentrations less than 250 mg/dL were excluded from subsequent experiments. Intragastric delivery of saline or phellopterin ((**3**), 0--2 mg/kg) was carefully performed for 4 weeks. An appropriate dosing volume of 0.5 mL of saline or phellopterin (**3**) was determined after weighing the animals daily. At the end of the experiment, blood samples were collected from the posterior vena cava of each animal under ether anesthesia. After obtaining the serum by centrifugation (2000 x *g*, 15 min), glucose, triglyceride and total-cholesterol levels were analyzed using a HEMAVET950 analyzer (Drew, USA).

4.4. Cell culture and adipocyte differentiation {#sec4.4}
-----------------------------------------------

Mouse 3T3-L1 preadipocytes (American Type Culture Collection (Manassas, VA, USA)) were incubated in DMEM containing 10% BCS along with 100 U/mL penicillin and 100 mg/mL streptomycin under 5% CO~2~, at 37 °C. Cells in the confluent state were cultured in DMEM supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 10 μg/mL insulin, 0.25 μM dexamethasone and 10% FBS for 2 days, and then transferred into DMEM containing 10% FBS only.

The 3T3-L1 preadipocytes were treated with various concentrations of the isolated compounds for 9 days, and were compared to an untreated control and positive control. The cells were then immobilized with phosphate buffered saline (PBS) containing 3% formaldehyde for 1 hour at room temperature, and washed three times with PBS. In order to analyze the rate of adipocyte differentiation, the immobilized cells were treated using AdipoRed Assay Reagent for 10 minutes at room temperature and the degree of fluorescence was measured (485 nm excitation and 572 nm emission).

4.5. Quantitative RT-PCR analysis {#sec4.5}
---------------------------------

Total RNA was extracted from 3T3-L1 adipocytes, after induced differentiation for 8 days, using PureLink RNA Mini Kit (Ambion, USA). One microgram of the total RNA was reversely transcribed with oligo (dT) primers, using the enzyme and buffer supplied in the PrimeScriptⅡ 1st strand cDNA Synthesis kit (Takara, Japan). Quantitative RT-PCR (qRT-PCR) reactions were performed on a MX3005P (Stratagene, USA). The primers used in the experiments were as follows: PPARγ (forward primer: 5′-CAAGAATACCAAAGTGCGATCAA-3′, reverse primer: 5′-GAGCTGGGTCTTTTCAGAATAATAAG-3′) and β-actin (forward primer: 5′-GAGACCTTCAACACCCC-3′, reverse primer: 5′-GTGGTGGTGAAGCTGTAGCC-3′) [@bib15].

For qRT-PCR, SYBR Premix Ex Taq Ⅱ (Takara, Japan) was used. The thermal cycling profile consisted of a pre-incubation step at 95 °C for 10 min, followed by 40 cycles of 95 °C (15 s) and 60 °C (60 s). Relative quantitative evaluations of PPARγ and β-actin levels were performed by the comparative CT (cycle threshold) method [@bib16].

4.6. Statistical analysis {#sec4.6}
-------------------------

All results are presented as means ± the standard error of the mean. Statistical significance of group differences as determined with one-way analysis of variance, and individual differences between the means of groups were analyzed using a modified t-test with Bonferroni correction; ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 were considered significant.
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[^1]: ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01 *vs*. untreated control.

[^2]: All values (the means ± SEM) are expressed as a percentage of untreated control (n = 3).

[^3]: *Angelica dahurica* extract with methanol.

[^4]: No experiment.

[^5]: ^∗^*P* \< 0.05 *vs*. normal diet group.

[^6]: ^\#^*P* \< 0.05 *vs*. HFD with STZ injected group.
